Oklo (OKLO) shares rose 0.26% to $43.10 in late-morning trading after the company reported a major reactor milestone. Its Groves Isotope Test Reactor reached first criticality, meaning it achieved a controlled and self-sustaining nuclear chain reaction. The milestone supports Oklo’s push into advanced nuclear systems, isotope production, and future commercial deployments. Oklo, which went public in 2024 through a merger with a special-purpose acquisition company, is one of several venture-backed firms racing to commercialize next-generation reactor designs alongside competitors such as NuScale, TerraPower, and X-energy.

Oklo Stock Gains After Groves Reactor Milestone

Oklo completed the milestone in less than one year after breaking ground on the Groves facility. The project moved forward under the Department of Energy’s Reactor Pilot Program, which streamlined development and safety reviews. That framework allowed construction, commissioning, and operational preparations to advance alongside federal authorization work.

The company developed the reactor on private land and handled major construction activities internally. It also sourced or produced the necessary components, including reactor fuel and supporting operating systems. Those steps gave Oklo greater control over project timing, technical standards, and startup preparations.

The successful test strengthens Oklo’s position in the expanding advanced nuclear industry. It also suggests that smaller reactor projects can progress more quickly under coordinated regulatory and engineering structures. At the same time, Oklo still must show that similar execution can scale to larger commercial facilities, a hurdle that has challenged other advanced reactor developers. NuScale, for instance, terminated its flagship carbon-free power project in Utah in late 2023 amid rising costs, underscoring how difficult the path from demonstration to commercial deployment remains.

Reactor Success Supports Isotope Production Plans

Groves is part of Oklo Isotopes’ plan to expand domestic production for several strategic markets. Those markets include healthcare, industrial research, space technology, and national security applications. The reactor could help support future supplies of specialized isotopes used across those sectors. Domestic isotope production has taken on added strategic importance as the United States has historically depended on foreign reactors for critical medical isotopes such as molybdenum-99, the precursor to technetium-99m used in diagnostic imaging.

The project also gave Oklo practical experience in procurement, construction, operations, safety preparation, and workforce training. The company can apply those lessons to future isotope plants and other advanced nuclear projects. As a result, it may be able to reduce technical delays and execution risks in later developments.

Groves also helped Oklo establish operating procedures and staff qualification programs. The company gained commissioning experience that could support faster deployment across its broader project pipeline. Those capabilities may strengthen operational reliability as Oklo moves beyond the test reactor stage.

Advanced Nuclear Expansion Provides Broader Context

Oklo continues to develop compact nuclear power systems for commercial and government customers. Its broader strategy includes powerhouses, fuel cycle services, and isotope production facilities. The Groves milestone now provides a working example of its development and operating approach.

The United States has increased support for domestic nuclear energy and critical fuel supply chains. Federal programs now aim to speed reactor testing while maintaining safety requirements and technical oversight. That policy environment has created new opportunities for companies developing advanced reactor designs. The Advanced Reactor Demonstration Program, authorized under the Energy Act of 2020, has channeled funding toward multiple reactor developers working toward deployment in the late 2020s and early 2030s.

Still, Oklo faces the commercial challenges common to many early-stage nuclear companies. These include project financing, licensing timelines, fuel availability, construction costs, and customer adoption. Even so, Groves gives the company measurable progress beyond design plans and development targets.